Is Cellectar Biosciences, Inc. (CLRB) a Buy, Sell, or Hold?
Cellectar Biosciences, Inc.
NASDAQ:CLRB
$2.63 USD
$0 (0.0%)
- Volume
- 44.28K
- Average Volume
- 1.07M
- Market Capitalization
- $8.4M
- P/E Ratio
- -0.36
- Dividend Yield
- 0.00%
- Price Target
- $11.00
- Year High
- $6.52
- Year Low
- $2.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.90
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | James V. Caruso |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CLRB |
| CUSIP | 15117F880 |
| CIK | 0001279704 |
| Web | https://www.cellectar.com |
| Phone | 608 441 8120 |
| Currency | USD |
| Employees | 11 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.32 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.90 |
| Quick Ratio | 1.90 |
| Cash Ratio | 1.71 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -4.38 |
| Price / Cash Flow | -0.45 |
| Price / Book | 2.36 |
Price Target and Rating
| Average Stock Price Forecast | $11.00 |
| High Stock Price Forecast | $11.00 |
| Low Stock Price Forecast | $11.00 |
| Forecast Upside/Downside | -76.09% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-8.35 |
| Trailing P/E Ratio | -0.36 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-21.79M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -264.79% |
| Return on Assets | -187.42% |
Financials Score
| AltmanZ Score | -39.50 |
| Piotroski Score | 1.00 |
| Working Capital | 4.39M |
| Total Assets | 11.12M |
| Ebit | -20.84M |
| Market Cap | 8.62M |
| Total Liabilities | 6.4M |
Poll Results
About Cellectar Biosciences, Inc. (NASDAQ:CLRB) Stock
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm a ... lso participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
2026-06-01 08:05:00
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3 Confirmatory Clinical Trial in 4Q26 FLORHAM PARK, N. J. , June 01, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that efficacy results from a subset of patients treated with iopofosine I 131 immediately post-Bruton Tyrosine Kinase inhibitor (BTKi) therapy in the Company's Phase 2 CLOVER WaM clinical trial of iopofosine I 131 to treat relapsed or refractory (r/r) Waldenström macroglobulinemia (WM) will be highlighted today in a poster presentation at the American Society of Clinical Oncology Annual Meeting (ASCO) taking place May 29-June 2, 2026 in Chicago, Illinois.
2026-06-01 08:05:00
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
2026-05-14 11:50:50
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-14 07:15:00
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-14 07:15:00
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)
2026-05-11 08:05:00
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time.
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
2026-05-07 13:00:21
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What's Going With Cellectar Biosciences Stock On Wednesday?
2026-05-06 09:17:04
Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing efforts.
Frequently Asked Questions
-
What is the current Cellectar Biosciences, Inc. (CLRB) stock price?
-
Cellectar Biosciences, Inc.(NASDAQ:CLRB) stock price is $2.63 in the last trading session. During the trading session, CLRB stock reached the peak price of $6.52 while $2.2 was the lowest point it dropped to. The percentage change in CLRB stock occurred in the recent session was 0.0% while the dollar amount for the price change in CLRB stock was $0.
-
CLRB's industry and sector of operation?
-
The NASDAQ listed CLRB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CLRB?
-
Chad J. Kolean | Vice President, Chief Financial Officer & Secretary
James V. Caruso | President, Chief Executive Officer & Director
Jarrod Longcor | Chief Operating Officer
|
| -
How many employees does CLRB have?
-
Number of CLRB employees currently stands at 11. CLRB operates from 100 Campus Drive, Florham Park, NJ 07932, US.
-
Link for CLRB official website?
-
Official Website of CLRB is: https://www.cellectar.com
-
How do I contact CLRB?
-
CLRB could be contacted at phone #608 441 8120 and can also be accessed through its website. CLRB operates from 100 Campus Drive, Florham Park, NJ 07932, US.
-
How many shares of CLRB are traded daily?
-
The average number of CLRB shares traded daily for last 3 months was 1.07M.
-
What is the market cap of CLRB currently?
-
The market value of CLRB currently stands at $8.4M with its latest stock price at $2.63